Each company has a bullish case, but three stand out as great long-term buys.The Dow Jones, formally known as the Dow Jones Industrial Average (DJIA), is one of the U.S. stock market's three main indexes, alongside the S&P 500 and Nasdaq Composite. It tracks 30 of the largest American companies on the market, aiming to give insight into the health of the U.S. stock market.Since the Dow Jones typically tracks large, mature companies, those companies generally pay a dividend. The only exceptions are Amazon, w ...

当地时间周一，美股三大指数集体收跌。道指跌0.09%，报48416.56点；纳指跌0.59%，报23057.41点；标普500指数跌 0.16%，报6816.51点。热门中概股普跌，纳斯达克中国金龙指数收跌2.17%。 个股方面，特斯拉涨超3%，创近一年新高，市值一夜增加超530亿美元。根据福布斯数据，公司CEO马斯克也成为了历史 上首位身家达到或超过6000亿美元的人。另外，iRobot大跌超72%，公司上周日申请破产保护，并计划由其中国主要供应 商、代工厂接盘并退市。 还值得投资关注的是，纳斯达克计划于周一向美国证券交易委员会提交文件，拟推出股票近乎全天候交易机制，将股票及 交易所交易产品的交易时长从每周五个交易日的16小时延长至23小时。 特斯拉股价创近一年新高 马斯克身价突破6000亿美元 当地时间周一，在科技股的"拖累"下，美股表现平平。截至收盘，美股三大指数集体飘绿。道指跌41.49点，跌幅0.09%， 报48416.56点；纳指跌137.76点，跌幅0.59%，报23057.41点；标普500指数跌10.90点，跌幅0.16%，报6816.51点。 大型科技股多数下跌，博通跌超5%，苹果、亚马逊 ...

当地时间12月15日，美股三大指数集体收跌，道指跌0.09%，纳指跌0.59%，标普500指数跌0.16%。 博通跌超5%；苹果、亚马逊涨超1%；特斯拉涨超3%，市值一夜增加537亿美元（约合人民币3786亿元）。 埃隆·马斯克距离成为全球首位"万亿美元"又迈出了巨大一步，根据福布斯数据，马斯克的身家达到了6770亿美元。他也由此成为历史上首位身家达到或超 过6000亿美元的人，此前从未有人突破5000亿美元大关。 加密矿企、货币储备概念跌幅居前，Hut8跌超14%，Circle跌超9%，Coinbase跌超6%。汽车制造、贵金属、旅游、减肥药板块走高，丰田汽车、礼来涨超 3%，安进、辉瑞、罗氏涨超2%。 iRobot跌72.69%。12月15日，随着破产重组方案（RSA）的尘埃落定，扫地机器人巨头、美国科技象征之一的iRobot正式破产，股票价值归零。 比特币两周来首次跌破8.6万美元，随着全球最大的加密货币进一步滑入熊市区域，投资者情绪走弱。 分析人士表示，比特币在滑向其近期交易区间的下限，而且每当价格出现反弹，都会遇到在10月初纪录高位附近买入的投资者抛售。周一比特币一度下跌 3.3%至85578美元， ...

New York, Dec. 12, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) recognizes the U.S. Food and Drug Administration (FDA) approval of Amgen’s UPLIZNA® (inebilizumab-cdon) for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) and anti-muscle specific tyrosine kinase (MuSK) antibody positive. This is the first and only CD19-Targeted B-Cell therapy approved for gMG. The approval offers patients a new treatment option that has the potenti ...

Key Takeaways Amgen wins FDA approval for Uplizna in generalized myasthenia gravis for adults with key antibody profiles.The drug offers twice-yearly dosing and showed strong efficacy in the phase III MINT study.The approval expands Amgen's rare disease portfolio as Uplizna enters a competitive gMG market.Amgen (AMGN) announced that the FDA has approved its rare disease drug Uplizna (inebilizumab) for a new indication — generalized myasthenia gravis (gMG). The drug is approved to treat the disease in adults ...

® THOUSAND OAKS, Calif., Dec. 11, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA (inebilizumab-cdon) for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) and anti-muscle specific tyrosine kinase (MuSK) antibody positive. The approval offers patients a new targeted treatment option that has the potential for long-term disease control with just two doses a year, after two in ...

富国银行将安进的目标价从300美元上调至325美元，维持"持有"评级。(格隆汇) ...

Basius77 / Shutterstock.com Quick Read PepsiCo generated $18.8B in operating cash flow in 2024 and maintains 52+ years of consecutive dividend increases. Chevron’s 95% payout ratio from earnings signals risk despite strong 2.67x cash flow coverage. AbbVie’s 501% earnings payout ratio is offset by 58.6% cash flow payout from $18.8B operating cash flow. If you’re thinking about retiring or know someone who is, there are three quick questions causing many Americans to realize they can retire earlier ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward- looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeOne Medicines Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla (apremilast), our acqui ...